# Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

> **NCT04779879** · PHASE2 · COMPLETED · sponsor: **Vir Biotechnology, Inc.** · enrollment: 354 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Sotrovimab (Gen1)
- **BIOLOGICAL:** Sotrovimab (Gen2)
- **BIOLOGICAL:** Sotrovimab (Gen2)

## Key facts

- **NCT ID:** NCT04779879
- **Lead sponsor:** Vir Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-18
- **Primary completion:** 2021-08-20
- **Final completion:** 2022-04-06
- **Target enrollment:** 354 (ACTUAL)
- **Last updated:** 2023-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04779879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04779879, "Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04779879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*